412 related articles for article (PubMed ID: 23724912)
1. Case of neuro-Behçet's disease successfully maintained a remission using infliximab for 2 years.
Kanemaru H; Makino T; Jinnin M; Yonemitsu A; Makino K; Ihn H
J Dermatol; 2013 Aug; 40(8):632-4. PubMed ID: 23724912
[TBL] [Abstract][Full Text] [Related]
2. Successful treatment of long-standing neuro-Behçet's disease with infliximab.
Sarwar H; McGrath H; Espinoza LR
J Rheumatol; 2005 Jan; 32(1):181-3. PubMed ID: 15630746
[TBL] [Abstract][Full Text] [Related]
3. Remission of Behcet's disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report.
Gulli S; Arrigo C; Bocchino L; Morgante L; Sangari D; Castagna I; Bagnato GF
BMC Musculoskelet Disord; 2003 Aug; 4():19. PubMed ID: 12946278
[TBL] [Abstract][Full Text] [Related]
4. Infliximab monotherapy for neuro-Behçet's disease: a case report.
Di Filippo M; Di Gregorio M; Nannini C; Gaetani L; Gallina C; Floridi P; Sarchielli P; Calabresi P; Cantini F
J Neurol Sci; 2014 Dec; 347(1-2):389-90. PubMed ID: 25456463
[No Abstract] [Full Text] [Related]
5. Infliximab therapy in parenchymal neuro-Behçet's disease: A single-center experience.
Yalcin Kehribar D; Gunaydin S; Ozgen M
Int J Rheum Dis; 2021 Oct; 24(10):1302-1307. PubMed ID: 34427044
[TBL] [Abstract][Full Text] [Related]
6. Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.
Accorinti M; Pirraglia MP; Paroli MP; Priori R; Conti F; Pivetti-Pezzi P
Jpn J Ophthalmol; 2007; 51(3):191-6. PubMed ID: 17554481
[TBL] [Abstract][Full Text] [Related]
7. [Behcet's refractory uveitis treated successfully by infliximab].
Mahfoudhi M; Hariz A; Ben Abdelghani K; Turki S; Kheder A
Tunis Med; 2014 Jan; 92(1):41-2. PubMed ID: 24879172
[No Abstract] [Full Text] [Related]
8. A case of intestinal Behçet's disease treated with infliximab monotherapy who successfully maintained clinical remission and complete mucosal healing for six years.
Maruyama Y; Hisamatsu T; Matsuoka K; Naganuma M; Inoue N; Ogata H; Iwao Y; Kanai T; Hibi T
Intern Med; 2012; 51(16):2125-9. PubMed ID: 22892489
[TBL] [Abstract][Full Text] [Related]
9. [Recent aspects of Neuro-Behcet's disease].
Hirohata S
Brain Nerve; 2013 Nov; 65(11):1245-53. PubMed ID: 24200602
[TBL] [Abstract][Full Text] [Related]
10. Neuro-behçet's disease in South Korea: clinical characteristics and treatment response.
Yoon DL; Kim YJ; Koo BS; Kim YG; Lee CK; Yoo B
Int J Rheum Dis; 2014 May; 17(4):453-8. PubMed ID: 24506839
[TBL] [Abstract][Full Text] [Related]
11. Successful treatment of severe Behçet's disease with infliximab in an Italian Olympic athlete.
Olivieri I; Latanza L; Siringo S; Peruz G; Di Iorio V
J Rheumatol; 2008 May; 35(5):930-2. PubMed ID: 18464316
[TBL] [Abstract][Full Text] [Related]
12. Successful use of infliximab in a patient with neuro-Behçet's disease.
Abalos-Medina GM; Sánchez-Cano D; Ruiz-Villaverde G; Ruiz-Villaverde R; Quirosa Flores S; Raya Alvarez E
Int J Rheum Dis; 2009 Sep; 12(3):264-6. PubMed ID: 20374357
[TBL] [Abstract][Full Text] [Related]
13. The effect of anti-tumour necrosis factor alpha (infliximab) on sight-threatening uveitis in a patient with Behçet's disease.
Morris DS; Gavin MP; Sturrock RD
Adv Exp Med Biol; 2003; 528():557-9. PubMed ID: 12918763
[No Abstract] [Full Text] [Related]
14. Evaluation of the long-term efficacy and safety of infliximab treatment for uveitis in Behçet's disease: a multicenter study.
Takeuchi M; Kezuka T; Sugita S; Keino H; Namba K; Kaburaki T; Maruyama K; Nakai K; Hijioka K; Shibuya E; Komae K; Hori J; Ohguro N; Sonoda KH; Mizuki N; Okada AA; Ishibashi T; Goto H; Mochizuki M
Ophthalmology; 2014 Oct; 121(10):1877-84. PubMed ID: 24950593
[TBL] [Abstract][Full Text] [Related]
15. Antitumor necrosis factor-alpha therapy for early postoperative recurrence of gastrointestinal Behçet's disease: report of a case.
Byeon JS; Choi EK; Heo NY; Hong SC; Myung SJ; Yang SK; Kim JH; Song JK; Yoo B; Yu CS
Dis Colon Rectum; 2007 May; 50(5):672-6. PubMed ID: 17216141
[TBL] [Abstract][Full Text] [Related]
16. Behçet's ileocolitis: successful treatment with tumor necrosis factor-alpha antibody (infliximab) therapy: report of a case.
Kram MT; May LD; Goodman S; Molinas S
Dis Colon Rectum; 2003 Jan; 46(1):118-21. PubMed ID: 12544532
[TBL] [Abstract][Full Text] [Related]
17. Treatment of intestinal Behçet's syndrome with chimeric tumour necrosis factor alpha antibody.
Travis SP; Czajkowski M; McGovern DP; Watson RG; Bell AL
Gut; 2001 Nov; 49(5):725-8. PubMed ID: 11600479
[TBL] [Abstract][Full Text] [Related]
18. Behcet's disease with life-threatening haemoptoe and pulmonary aneurysms: complete remission after infliximab treatment.
Baki K; Villiger PM; Jenni D; Meyer T; Beer JH
Ann Rheum Dis; 2006 Nov; 65(11):1531-2. PubMed ID: 17038456
[No Abstract] [Full Text] [Related]
19. Adalimumab for sight-threatening uveitis in Behçet's disease.
Mushtaq B; Saeed T; Situnayake RD; Murray PI
Eye (Lond); 2007 Jun; 21(6):824-5. PubMed ID: 16601736
[TBL] [Abstract][Full Text] [Related]
20. Long-lasting remission of severe Behçet's disease after the end of infliximab therapy.
Olivieri I; Padula A; Leccese P; D'Angelo S; Giasi V
J Rheumatol; 2009 Apr; 36(4):855. PubMed ID: 19342728
[No Abstract] [Full Text] [Related]
[Next] [New Search]